Five outstanding HBS alumni will work with inventors from Harvard University’s research laboratories to promote the commercialization of innovative life science-oriented technologies with significant market potential.

NEWTON, Mass.--(BUSINESS WIRE)--Macrolide Pharmaceuticals, a new company with groundbreaking technology to develop novel antibiotics, completed a Series A financing of $22 million led by Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing follows a worldwide license agreement between Harvard's Office of Technology Development and the company, providing exclusive rights to the technology.

The Blavatnik Fellowship in Life Science Entrepreneurship kicked-off a second exciting year with reception to welcome the new fellows.

Professors Dan Finley and Randy King are poised to change the future for those who suffer from neurodegenerative diseases. With the help of OTD’s Biomedical Accelerator, they were able to build on this foundation and advance the frontiers of science and healthcare.